UA109492C2 - METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS - Google Patents

METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS

Info

Publication number
UA109492C2
UA109492C2 UAA201400137A UAA201400137A UA109492C2 UA 109492 C2 UA109492 C2 UA 109492C2 UA A201400137 A UAA201400137 A UA A201400137A UA A201400137 A UAA201400137 A UA A201400137A UA 109492 C2 UA109492 C2 UA 109492C2
Authority
UA
Ukraine
Prior art keywords
sessions
halo
days
aerosol
psoriasis patients
Prior art date
Application number
UAA201400137A
Other languages
Russian (ru)
Ukrainian (uk)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to UAA201400137A priority Critical patent/UA109492C2/en
Publication of UA109492C2 publication Critical patent/UA109492C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

Винахід належить до галузі медицини, зокрема дерматології, та стосується способу лікування хворих на псоріаз, що включає застосування ропних ванн, грязьових аплікацій та штучного ультрафіолетового опромінення, причому хворим додатково призначають сеанси галоаерозольтерапії, причому концентрацію аерозолю в повітрі камери підтримують в межах 10-12 мг/м, розмір частинок солі складає 7-15 мкм при вмісті їх в аерозолі в кількості 50-60 %, а сеанси галоаерозольтерапії проводять щоденно тривалістю 60 хвилин протягом 15-18 днів лікування з одночасним призначенням внутрішнього прийому субаліну по одній дозі три рази в день за 30 хв до їди протягом 14 днів.The invention relates to medicine, in particular dermatology, and relates to a method of treating patients with psoriasis, including the use of baths, mud applications and artificial UV irradiation, with patients additionally assigned to sessions of halo aerosol therapy, and / m, the particle size of the salt is 7-15 microns when they are contained in the aerosol in the amount of 50-60%, and sessions of halo aerosol therapy is carried out daily for a duration of 60 minutes for 15-18 days of treatment with simultaneous pr determination of internal administration of subalin one dose three times a day for 30 min before meals for 14 days.

UAA201400137A 2014-01-09 2014-01-09 METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS UA109492C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAA201400137A UA109492C2 (en) 2014-01-09 2014-01-09 METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201400137A UA109492C2 (en) 2014-01-09 2014-01-09 METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS

Publications (1)

Publication Number Publication Date
UA109492C2 true UA109492C2 (en) 2015-08-25

Family

ID=54772107

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201400137A UA109492C2 (en) 2014-01-09 2014-01-09 METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS

Country Status (1)

Country Link
UA (1) UA109492C2 (en)

Similar Documents

Publication Publication Date Title
MX2021000609A (en) Methods of treatment with cyp3a4 substrate drugs.
MX2021004821A (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy.
NZ630367A (en) Methods of treatment of pediatric solid tumor
MX2015011296A (en) Phototherapeutic device, method and use.
WO2014186453A3 (en) Apparatus and method for administering a medical device prescription
MX2017006938A (en) Combination therapy for treatment of cancer.
MX366502B (en) Compositions and methods for treating surface wounds.
CL2016001794A1 (en) Method for administering tasimelteon to a human patient that includes oral administration of an effective dose under fasting conditions to treat a circadian rhythm disorder or a sleep disorder, such as sleep-wake disorder other than 24 hours non-24 method for shorten the tmax of tasimelteon in a human patient who is being treated with tasimelteon.
JOP20200031A1 (en) Methods of treatment of osteoarthritis with transdermal cannabidiol gel
CL2018002734A1 (en) Vitamin D treatment methods
AR103118A1 (en) ANAMORELINE-BASED MEDICAL TREATMENTS
MX2019003751A (en) Therapeutic protein.
ATE447974T1 (en) COMBINATION THERAPY WITH AZD2171 AND 5-FU AND/OR CPT-11
TW201642906A (en) Fixed dose combination for pain relief without edema
UA109492C2 (en) METHOD OF RESTORATIVE TREATMENT OF PSORIASIS PATIENTS
EA202091653A1 (en) MINOCYCLINE FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES
MX2015008676A (en) Metadichol r liquid and gel nanoparticle formulations.
UA113183C2 (en) METHOD OF ADIATION TREATMENT
EA202190294A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EA202190291A1 (en) COMBINATION THERAPY FOR CANCER TREATMENT
EA201600229A1 (en) BIS (5-AMINO-1,4-DIOXO-1,2,3,4-TETRAHYDRO-PHTHALAZIN-2-AIHs) ZINC, METHOD FOR ITS OBTAINING, PHARMACEUTICAL COMPOSITION ON ITS BASIS, MEDICAL MEANS ON ITS BASIS, SPECIAL SYSTEMS AND HEATS ARE BASED, ITEM-BASED, MEDICAL MEANS ON ITS BASIS, SPECIAL TESTS TREATMENT OF GASTRITIS
UA96506U (en) METHOD OF TREATMENT OF NEUROPATHIES
UA97411U (en) Method for the treatment of patients with psoriasis
CN105687063A (en) Traditional Chinese medicine mask for treating acne rosacea
UA115711U (en) METHOD OF TREATMENT OF Hepatic Encephalopathy in Patients with Secondary Biliary Cirrhosis of the Liver